MXPA01006319A - Uso de los antagonistas del receptor para 5ht, para el tratamiento de sindrome de fatiga cronica. - Google Patents

Uso de los antagonistas del receptor para 5ht, para el tratamiento de sindrome de fatiga cronica.

Info

Publication number
MXPA01006319A
MXPA01006319A MXPA01006319A MXPA01006319A MXPA01006319A MX PA01006319 A MXPA01006319 A MX PA01006319A MX PA01006319 A MXPA01006319 A MX PA01006319A MX PA01006319 A MXPA01006319 A MX PA01006319A MX PA01006319 A MXPA01006319 A MX PA01006319A
Authority
MX
Mexico
Prior art keywords
medicine
preparation
treatment
relates
receptor antagonists
Prior art date
Application number
MXPA01006319A
Other languages
English (en)
Inventor
Welzel Dieter
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Publication of MXPA01006319A publication Critical patent/MXPA01006319A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invencion se refiere al uso de los antagonistas del receptor de 5HT3 para la preparacion de una medicina util en el tratamiento de sindrome de fatiga cronica.
MXPA01006319A 1998-12-22 1999-12-22 Uso de los antagonistas del receptor para 5ht, para el tratamiento de sindrome de fatiga cronica. MXPA01006319A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19859406 1998-12-22
PCT/DE1999/004071 WO2000037073A1 (de) 1998-12-22 1999-12-22 Verwendung von 5ht3-rezeptor-antagonisten zur therapie des chronischen müdigkeitssyndrom

Publications (1)

Publication Number Publication Date
MXPA01006319A true MXPA01006319A (es) 2003-06-06

Family

ID=7892223

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01006319A MXPA01006319A (es) 1998-12-22 1999-12-22 Uso de los antagonistas del receptor para 5ht, para el tratamiento de sindrome de fatiga cronica.

Country Status (9)

Country Link
US (2) US6740672B1 (es)
EP (1) EP1140076A1 (es)
JP (1) JP2002532549A (es)
CN (1) CN1161118C (es)
AU (1) AU759250B2 (es)
BR (1) BR9916495A (es)
CA (1) CA2356246A1 (es)
MX (1) MXPA01006319A (es)
WO (1) WO2000037073A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014429A1 (ja) * 2002-08-09 2004-02-19 Mitsubishi Pharma Corporation 精神疾患発症脆弱性制御剤
MX2007010063A (es) 2005-02-17 2008-01-16 Albany Molecular Res Inc Benzoxazol-carboxamidas para el tratamiento de la naucea y el vomito inducidos por quimioterapia y sindrome del intestino irritable con diarrea predominante.
MX2012000572A (es) * 2009-07-14 2012-05-08 Albany Molecular Res Inc Moduladores del receptor 5-hidroxi triptamina 3 (5-ht3), metodos para su realización y uso de los mismos.
KR101778439B1 (ko) 2015-04-27 2017-09-14 울산대학교 산학협력단 자연살해세포 활성화제를 유효성분으로 함유하는 면역증강 및 항암활성증진용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
CA2112487C (en) * 1991-06-26 2003-04-15 James W. Young Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
GB9412995D0 (en) * 1994-06-28 1994-10-26 Prendergast Kenneth F Safety enhancing pharmaceutical compositions of an active indazole
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5614523A (en) * 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems

Also Published As

Publication number Publication date
WO2000037073A1 (de) 2000-06-29
US20040204467A1 (en) 2004-10-14
BR9916495A (pt) 2001-09-04
CN1333684A (zh) 2002-01-30
AU759250B2 (en) 2003-04-10
EP1140076A1 (de) 2001-10-10
CN1161118C (zh) 2004-08-11
CA2356246A1 (en) 2000-06-29
AU2428500A (en) 2000-07-12
JP2002532549A (ja) 2002-10-02
US6740672B1 (en) 2004-05-25

Similar Documents

Publication Publication Date Title
WO1999017755A3 (en) Medicaments
BG102726A (en) Combined therapy for osteoporosis
MY127290A (en) New use of flibanserin
DE60035232D1 (de) (S,S)-Reboxetine zur Behandlung von chronischen Erschöpfungssyndrom
AP2004002982A0 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
WO2002036562A3 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
IL196301A0 (en) Medicament for the treatment of hapatitis c
HK1040397A1 (en) substituted benzopyran analogs for the treatment of inflammation.
IL145068A0 (en) The use of glycine betaine to prepare a pharmaceutical composition
WO2001081343A3 (en) Compounds for treating fibromyalgia and chronic fatigue syndrome
GB0111186D0 (en) Novel compounds
ZA200201788B (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
DK0973544T3 (da) Immuntolerant prothrombinkomplekspræparat
GB9815618D0 (en) Treatment of dyskinesia
BG104038A (en) Use of specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing
PL350917A1 (en) C16 unsaturated fp-selective prostaglandins analogs
HK1018265A1 (en) Piperazino derivatives as neurokinin antagonists
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
GR3034757T3 (en) Compositons for the treatment of chronic fatigue syndrome.
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
MXPA01006319A (es) Uso de los antagonistas del receptor para 5ht, para el tratamiento de sindrome de fatiga cronica.
MXPA04003910A (es) Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar.
HK1033876A1 (en) Use of nmda antagonists for treatment of irritablebowel syndrome.
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia